ストックスクリーナーアプリを入手
115.22
2.47%
2.78
プレマーケット:
115.36
0.14
+0.12%
Halozyme Therapeutics Inc (HALO) 最新ニュース
Halozyme Therapeutics, Inc. (HALO) Stock forecasts - Yahoo Finance UK
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo! Finance Canada
Halozyme stock falls 2.34% after strong quarterly growth - AD HOC NEWS
$1000 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth This Much Today - Benzinga
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now - finance.yahoo.com
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength? - finance.yahoo.com
Halozyme Therapeutics, Inc. (HALO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Form 8K Halozyme Therapeutics Inc For: 22 September By Investing.com - Investing.com Canada
Halozyme Therapeutics completes $1.5 billion convertible notes offering By Investing.com - Investing.com Canada
Halozyme Therapeutics completes $1.5 billion convertible notes offering - Investing.com
Halozyme Therapeutics Raises $1.5 Billion in 1.50% Convertible Notes, Adds Capped Calls - TradingView
Halozyme Therapeutics, Inc. (HALO) stock price, news, quote and history - sg.finance.yahoo.com
Halozyme Therapeutics stock rises as $1.3 billion convertible notes fuel growth guidance - AD HOC NEWS
Halozyme (HALO) Just Made A $1.3B Bet On Itself - finance.yahoo.com
Latham & Watkins Advises on Halozyme Therapeutics, Inc.’s Upsized US$1.3 Billion Convertible Senior Notes Offering - Latham & Watkins LLP
(HALO) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate - Zacks Investment Research
Halozyme Therapeutics (HALO) Proposes $1.05B in Convertibles. Is More Time Worth the Cost? - finance.yahoo.com
Halozyme Therapeutics stock edges higher as investors weigh Q2 growth and pipeline risk - AD HOC NEWS
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) - easternprogress.com
Is Halozyme Therapeutics (HALO) Fully Valued As Growth Calls And Partnerships Draw Fresh Attention? - webull.com
Halozyme Therapeutics Prices $1.3 Billion Convertible Senior Notes with Additional $200 Million Overallotment Option - Kalkine Media
Dynatrace, Cava Group, Halozyme Therapeutics - TradingView
Halozyme Therapeutics, Etsy, Netflix - TradingView
Halozyme Therapeutics stock hits all-time high at 111.56 USD By Investing.com - Investing.com Nigeria
Halozyme Therapeutics stock hits all-time high at 111.56 USD - Investing.com
Halozyme prices $1.3B of 1.50% convertible notes due 2033, upsized with $200M option - TradingView
Halozyme Prices $1.3 Billion Convertible Senior Notes Offering - marketscreener.com
HALO Looks 10.2% Overvalued on GF Value™ - GuruFocus
Halozyme prices $1.3B convertible notes to fund repurchases and growth initiatives - Pluang
Halozyme prices $1.3 billion convertible notes offering - Investing.com
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Prices Upsized $1.3B 1.50% Convertible Notes Due 2033 - TradingView
HALOZYME THERAPEUTICS (NASDAQ: HALO) Announces $1.05 Billion Convertible Senior Notes Offering with $150 Million Option - Kalkine Media
Halozyme Therapeutics Plans $1.05 Billion Offering of Convertible Notes - marketscreener.com
Halozyme Therapeutics plans a $1.05B convertible notes sale - TradingView
Years of RSU awards set for sale by Halozyme (NASDAQ: HALO) director - stocktitan.net
Halozyme plans $1.05 billion convertible notes offering - Investing.com
Halozyme proposes $1.05B convertible notes due 2033, with $150M option - TradingView
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Plans $1.05B Convertible Notes Due 2033 - TradingView
Is Halozyme Therapeutics (HALO) Fully Priced Ahead Of Its September Conference Run? - finance.yahoo.com
Halozyme Therapeutics, Inc. at HC Wainwright Global Investment Conference Transcript - GuruFocus
Zacks.com featured highlights include Halozyme Therapeutics, Avnet, BILL and Venture Global - Yahoo Finance
Halozyme Therapeutics, Inc. at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Halozyme president and CEO Helen Torley sells $6.4 million in stock By Investing.com - Investing.com South Africa
Halozyme president and CEO Helen Torley sells $6.4 million in stock - Investing.com Australia
Halozyme (NASDAQ: HALO) CEO exercises options, sells 60,000 shares - Stock Titan
Halozyme Therapeutics(HALO.US) Officer Sells US$6.44 Million in Common Stock - Moomoo
Record Revenue Growth Boosts Halozyme Shares - FXEmpire
Why (HALO) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Alteogen Licenses ALT-B4 to Novartis in Deal Worth Up to $3.2 Billion, Reaffirming Value of SC Formulation Platform - finance.biggo.com
Halozyme at Wells Fargo healthcare conference: subQ push gains steam By Investing.com - Investing.com UK
Transcript : Halozyme Therapeutics, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 03 - marketscreener.com
Halozyme Therapeutics (NASDAQ:HALO) Screens Well on High Growth Momentum and Breakout Setup - ChartMill
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Biotech Powerhouse with a Revenue Growth of 47.70% - directorstalkinterviews.com
Biotech Stocks At 52-Week HighsATTO, HALO, IKT, TVTX, ATRC - RTTNews
Halozyme Therapeutics | SCHEDULE 13G: Others - Moomoo
Halozyme Therapeutics stock hits all-time high at 109.69 USD By Investing.com - Investing.com Nigeria
Halozyme (NASDAQ: HALO) awards board member new RSUs and options vesting at 2027 meeting - Stock Titan
1.11%
1.87%
大文字化:
|
ボリューム (24 時間):